Search
Search
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
Show Description +
How do retina specialists define “disease control” in patients with Wet AMD and DME? And how is retinal fluid related to disease control? Moderator Diana V. Do, MD, explores these questions with panelists Charles C. Wykoff, MD, PhD; David S. Chin Yee, MD; and Esther L. Kim, MD, and asks what treatment distinctions exist between Wet AMD and DME.
Posted: 11/13/2023
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
How do retina specialists define “disease control” in patients with Wet AMD and DME? And how is retinal fluid related to disease control? Moderator Diana V. Do, MD, explores these questions with panelists Charles C. Wykoff, MD, PhD; David S. Chin Yee, MD; and Esther L. Kim, MD, and asks what treatment distinctions exist between Wet AMD and DME.
Posted: 11/13/2023
Contemporary Challenges to Treating Wet Age-related Macular Degeneration and Diabetic Macular Edema
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Visit us online: regeneron.com
Follow Regeneron
Copyright © 2023 Regeneron Pharmaceuticals Inc. All rights reserved.
10/2023
US.OPH.23.09.0002
_1704488282.png?auto=compress,format&w=180)
%20(1)_1704487948.png?auto=compress,format&w=180)